Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.
Patients will be cohort-wise treated with clinically available kinase inhibitors for 2 weeks
prior to standard palliative treatment. Five patients will be included in each of eight drug
cohorts. Biopsies will be performed to determine intratumoral drug concentrations and to
compare tissue (phospho)proteomic and kinase activity profiles before and during therapy.
Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
concentrations of intratumoral kinase inhibitors upon 2 weeks of treatment
H.M.W. Verheul, MD, PhD
VU Medical Center Amsterdam
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)